SCHEMBL279857

SCHEMBL279857

CC(=O)NC1CCN(C(=O)c2cc(C)ccc2Cl)C1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 2/20 0.47
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 2/20 0.43
KDM5B Q9UGL1 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 2/20 0.41
ALOX15 P16050 1/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC2 Q92769 3/20 0.41
HDAC3 O15379 2/20 0.41
EPHX2 P34913 1/20 0.40
MEN1 O00255 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280261 0.81 HCRTR1 (0.53) KDM5AKDM5B
SCHEMBL4242381 0.80 KDM1A (0.52) ALDH1A1HPGDTSHRLMNATP53
SCHEMBL3653977 0.80 KDM1A (0.52) ALDH1A1HPGDTSHRLMNATP53
SCHEMBL279835 0.79 KMT2A (0.55) KDM5AALDH1A1HPGDKDM5BLMNA
SCHEMBL12948013 0.79 KMT2A (0.55) KDM5AALDH1A1HPGDKDM5BLMNA
SCHEMBL279836 0.78 EPHX2 (0.59) KDM5AALDH1A1HPGDTDP1KMT2A
SCHEMBL280293 0.76 KDM5A (0.56) KDM5AKDM5B
SCHEMBL29268416 0.75 PARP1 (0.49) ALDH1A1HPGDLMNANPC1RAB9A
SCHEMBL4238382 0.75 HCRTR1 (0.49)
SCHEMBL4238388 0.75 HCRTR1 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KDM5A 4289/4885ALDH1A1 2047/4885HPGD 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.